EP0885020A1 - Compositions de fermeture tissulaire et procedes d'utilisation - Google Patents

Compositions de fermeture tissulaire et procedes d'utilisation

Info

Publication number
EP0885020A1
EP0885020A1 EP97907707A EP97907707A EP0885020A1 EP 0885020 A1 EP0885020 A1 EP 0885020A1 EP 97907707 A EP97907707 A EP 97907707A EP 97907707 A EP97907707 A EP 97907707A EP 0885020 A1 EP0885020 A1 EP 0885020A1
Authority
EP
European Patent Office
Prior art keywords
factor
tissue
component
fibrinogen
thromboplastin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97907707A
Other languages
German (de)
English (en)
Inventor
David H. Sierra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cohesion Corp
Original Assignee
Cohesion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cohesion Corp filed Critical Cohesion Corp
Publication of EP0885020A1 publication Critical patent/EP0885020A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043—Mixtures of macromolecular materials

Definitions

  • This invention relates to fibrin based tissue sealant compositions and more specifically, to thromboplastin-containing tissue sealant compositions which are capable of effectuating formation of a fibrin based clot in situ..
  • Blood coagulation is the end result of a complex cascade of multiple proteins and other cofactors, culminating in the formation of fibrin strands.
  • Fibrin formed from the precursor fibrinogen, is the protein which holds blood clots together.
  • the coagulation cascade is described as consisting of separate pathways: the extrinsic pathway and the intrinsic pathway. (Rapaport and Rao Thromb. Haemostasis 74.7-17 (1995 ⁇ 1.
  • the "extrinsic” pathway is dependent upon thromboplastin, and the "intrinsic” pathway is independent of thromboplastin.
  • the pathways converge upon the generation of thrombin, which in combination with calcium ions, converts fibrinogen to fibrin, and Factor XIII to
  • a fibrin sealant exploits this final stage ofthe coagulation cascade and historically has been designed as a two-component system, analogous to a two-component epoxy adhesive.
  • the first component consists of fibrinogen and Factor XIII; which can be equated to the "resin" component of an adhesive composition.
  • Thrombin and calcium ions make up the second component, which acts ast the catalyst ofthe resin.
  • the two components may be applied sequentially or simultaneously by a syringe or by spraying. When they come in contact with one another, fibrin is formed from the fibrinogen. Fibrin sealants are used for hemostasis, as well as tissue sealing in patients on heparin or with coagulation deficiencies.
  • Fibrin sealants can partially or totally preclude the use of sutures and thereby avoid inflammatory reactions (DePalma et al., Transfusion 33:717-720 (1993)).
  • fibrin sealant adhesive systems see Sierra, J. Biomaterials Appl. 7:309-352 (1993).
  • U.S. Patent No. 5,290,552 describes a dual-component system comprising fibrinogen, Factor XIII and collagen as one component; and thrombin and calcium ions as the other component. These two components are then mixed together just prior to use.
  • U.S. Patent No. 4,600,574 describes a surgical adhesive comprising a flat web-like sheet of collagen, gelatin or polysaccharide which is coated with a solution of fibrinogen and Factor XIII, followed by lyophilization to form a matrix.
  • 4,453,939 describes a composition for the healing of wounds which comprises a web-like carrier comprised of collagen which is coated on one side with a mixture of: (1) a fibrinogen-containing component which contains fibrinogen and Factor XIII; and (2) a thrombin-containing component. Coagulation is initiated upon insertion ofthe web into the patient which results in hydration and activation.
  • Thromboplastin also referred to as tissue factor protein (TF)
  • TF tissue factor protein
  • U.S. Patent No. 5,091,363 describes a composition and method for the treatment of hemophilia A.
  • thromboplastin is used to determine the thromboplastin time (PT) of a patient as an indicator of clotting efficiency.
  • U.S. Patent No. 5,110,730 and PCT International Publication No. WO 94/11029 describe DNA segments defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form ofthe protein. Methods of producing tissue factor protein recombinantly and the recombinant protein also are disclosed. The protein is disclosed to be useful for modulating the binding of Factor VH VIIa by tissue factor in vivo. Diagnostic uses for detecting the presence of a thrombus or the amount of tissue factor in a body sample are disclosed.
  • European Patent Application Publication No. 0 278 776 discloses a tissue factor protein capable of correcting various bleeding disorders by inducing coagulation which is distinct from tissue thromboplastin because it lacks the naturally occurring lipid portion of the molecule.
  • DNA isolates coding for tissue factor protein and derivatives thereof, recombinant expression systems for recombinant expression ofthe DNA are disclosed. Methods of treating coagulation disorders using the compositions also are disclosed.
  • European Patent Application No. 0 347 262 discloses the sequence of a cDNA coding for human tissue factor and its use for the construction of recombinant expression vectors which in transformed hosts, produce human tissue factor apoprotein, soluble human tissue factor and truncated human tissue factor for clinical and diagnostic use.
  • the present invention relates to tissue sealant composition that are useful to promote tissue adhesion and/or hemostasis via fibrin formation at the site of administration.
  • the tissue sealant composition is prepared as a single component containing thromboplastin and fibrinogen, which can be supplied in purified form or by adding plasma.
  • the composition may further comprise calcium ions, and addition factors (also supplied in purified form or by adding plasma) such as Factors II, V, VII, X and XIII.
  • the tissue sealant composition is prepared in two parts (i.e. it is a "dual component system) which are mixed together before administration: one containing fibrinogen, and the other containing thromboplastin.
  • any or all ofthe aforementioned optional components can also be included in either ofthe two components.
  • mixing of the two components does not initiate fibrin formation, in which case the composition would necessarily have to be administered before complete gelling had occurred.
  • the tissue sealant composition reacts at the site of administration with tissues and/or blood, which supply an effective amount of calcium ions, Factors II, V, VII, X and XIII to cause the fibrinogen to be converted to fibrin.
  • tissue and/or blood which supply an effective amount of calcium ions, Factors II, V, VII, X and XIII to cause the fibrinogen to be converted to fibrin.
  • any of these optional components are not present in sufficient quantities at the site of administration to effect fibrin formation, they are added to the tissue sealant composition prior to administration.
  • the present invention additionally relates to a method for promoting tissue adhesion and/or hemostasis using any ofthe aforementioned compositions as further described below.
  • Figure 1 is a flow chart showing the blood coagulation cascade. (From Enzyme Research Laboratories, Inc., South Bend, IN.) The abbreviations for the various blood coagulation factors are included in Table I. MODE S-1 FOR CARRYING OUT THE INVENTION Blood coagulation is a complex cascade of events that results in formation of fibrin strands. Figure 1 illustrates the blood coagulation cascade. The various factors, their molecular weights and typical plasma concentrations are given in Table I.
  • tissue sealant refers to a composition which is effective to act as a tissue adhesive and/or hemostatic agent.
  • thromboplastin as the initiator of fibrin clot formation may improve the hemostatic qualities ofthe adhesive by virtue ofthe extrinsic pathway's efficiency in forming thrombi.
  • this pathway as depicted in Figure 1, thromboplastin complexes with and converts Factor VII to Vila, and then, in the presence of calcium ions, converts Factor X into Factor Xa, and Factor V into Va creating a "prothrombinase complex.”
  • Factor Xa (which uses Factor Va as a cofactor) converts Factor II (prothrombin) into thrombin. Thrombin then converts fibrinogen into fibrin which forms a clot, and also converts Factor XIII into Factor Xllla in the presence of calcium ions. Factor Xllla in turn causes covalent crosslinking ofthe fibrin clot which makes it more stable both mechanically and proteolytically.
  • the tissue sealant composition contains, as its primary elements, an effective amount of thromboplastin and fibrinogen. Additionally, the tissue sealant composition preferably contains calcium ions. In the case of a tissue sealant composition containing only thromboplastin, fibrinogen and calcium ions in a suitable delivery vehicle, all other factors (and other requirements) which are necessary to effect fibrin formation are found at the application site. However, not all application sites, especially those which are not actively bleeding, provide a sufficient source of these additional components. In this situation, the tissue sealant preferably contains all ofthe necessary factors required for fibrin formation, i.e. thromboplastin, fibrinogen, calcium ions and Factors II, V, VII, X and XIII.
  • the tissue sealant compositions are prepared as a single- component system.
  • the single-component system over conventional two-component fibrin sealant systems now in place.
  • No exogenous thrombin of either human or other source is required, especially in large quantities.
  • the need for large quantities of exogenous thrombin are eliminated in that very small amounts of thromboplastin enable the conversion of prothrombin to thrombin.
  • Another important advantage ofthe composition and its use is its that it eliminates the need for catalysis ofthe "resin", which facilitates uniform mixing, curing and subsequent strength ofthe material.
  • the convenience is improved in that only one delivery device or dosage unit is required to prepare and apply the material.
  • Thromboplastin can be obtained from brain or tissue extracts, or it can be prepared using recombinant techniques. Thromboplastin which is obtained from natural sources contains an amount of lipid associated therewith which is necessary for thromboplastin activity. Thromboplastin which is produced from recombinant techniques must be "lipidated” to restore its native activity. As used herein, the term "thromboplastin” refers to thromboplastin from natural sources, as well as lipidated thromboplastin produced using recombinant techniques. See, for example, U.S. Patent No. 5,314,695 which describes the lipidation procedure.
  • Recombinant thromboplastin is commercially available from Ortho Diagnostics (Raritan, N.J.) sold under the tradename RecombinPlastin® and Baxter Healthcare
  • thromboplastin extract sold under the tradename Innovin ® (Miami, FI.)
  • Methods of preparing purified thromboplastin are well known in the art and are described, for example in U.S. Patent Nos.: 5,254,350; 4,755,461; 5,270,451; 3,522,148; 3,522,148 and European Patent Publication No. 524 803 A2.
  • Purified constituents are commercially available or readily obtainable from human and animal blood fractions or can be recombinantly produced using methods well known to those of skill in the art. It should be appreciated that the constituents as noted herein can be obtained from any suitable animal source, e.g., human, bovine or porcine.
  • bovine fibrinogen is commercially available from Sigma Chemical Co. (Saint Louis, MO); Factors V, VII and XIII are commercially available from American Diagnostics Inc. (Greenwich, CT); Factor IX (human and bovine) is commercially available from Accurate Chemical & Scientific Corp. (Westbury, N.Y.) and American Diagnostic Inc. (Greenwich, CT); human and rabbit Factor VIII is commercially available from Accurate Chemical &
  • human Factor X can be purchased from American Diagnostics Inc (Greenwich, CT) or bovine Factor X can be purchased from Sigma Chemical Co. (St. Louis, MO).
  • Plasma can be used "as is" as a source for the various constituents after removal ofthe cellular components of blood by centrifugation.
  • plasma can be processed to prepare a plasma cryoprecipitate by freezing, thawing and further centrifugation, which can be used as a source of fibrinogen and Factor XIII.
  • Various factors can also be isolated from plasma which is in crystalline or amorphous form, or as a lyophilizate.
  • Factors II, V, VII and X can be obtained from a cryosupernatant of plasma.
  • Fibrinogen and Factor XIII can also be obtained from allogeneic or autologous plasma preparations.
  • Fibrinogen and Factor XIII may be obtained from the "resin" component of commercially available dual-component fibrin sealant compositions.
  • bovine fibrinogen can be obtained from a fibrin sealant preparation such as Tisseel ® (Immuno AG,
  • Factors II, V, VII and X can be obtained from anti-hemophilia B therapeutic agents (Octapharma, Immuno AG, Alpha Therapeutics, Baxter-Hyland and Armour Bayer).
  • Factor II may be produced by recombinant expression techniques as described in
  • the desired constituents are initially produced in soluble form and, where appropriate, are virally deactivated.
  • the components are purified from a native or natural source, they are provided in purified or substantially purified form.
  • Purified shall mean that the protein or factor of interest is substantially free of cellular and other biological components normally associated with the protein or factor in its native or natural environment in the cell or body fluid.
  • purified can be used to describe proteins and factors isolated from their native environment or isolated from a biological, non-naturally occurring environment such as when they are recombinantly produced in a host cell such as a Chinese Hamster Ovary cell which is commercially available from the American Type Culture Collection ("ATCC”; Rockville, MD).
  • ATCC American Type Culture Collection
  • compositions of this invention can include, in addition to the factors in forms as they appear in nature, i.e., in a "purified” state, analogs, muteins, conjugates, and homologues ofthe proteins or factors, provided that the biological activity of the factor is not substantially impaired.
  • “Substantially impaired” would include a greater than 50% reduction in the biological activity ofthe analog, homologue or mutein, as compared to native or natural protein or factor.
  • use of a term such as "thromboplastin”, in addition to thromboplastin from natural sources is intended to encompass all alternative forms of thromboplastin having a biological activity which is not substantially impaired, i.e. "thromboplastin equivalents.”
  • the biological activity of a protein or factor includes any feature of the polypeptide determined by suitable experimental investigation, including, but not limited to the experiments set forth herein relating to coagulation time and the ability to promote the formation of fibrin in situ.
  • the preferred single-component composition which contains thromboplastin, fibrinogen and all ofthe necessary extrinsic pathway factors (Factors II, V, VII, X and
  • XIII is prepared by mixing the constituents together either without calcium ions or an amount of calcium ions which is insufficient to effect gelation ( ⁇ 3mM) within an hour. Such compositions remain flowable for at least one hour, or until they come in contact with tissue and/or blood after administration. The additional Ca from blood or tissue permits the extrinsic pathway reactions to occur, which results in fibrin clot formation.
  • an effective amount ofthe individual components is an amount that, when combined as described herein and brought into contact with body tissues in situ, will induce the conversion of fibrinogen to fibrin which results in fibrin clot formation. Suitable concentrations for most ofthe factors correspond to a range present in normal human plasma and as provided in Table III, below. It should be assumed, although not always explicitely stated, that "effective amounts" ofthe components are used and inco ⁇ orated into the compositions of this invention.
  • compositions comprising a single tissue adhesive in combination with other constituents, such as stabilizers, preservatives, therapeutics collagen, collagen analogs and collagen conjugates.
  • stabilizers Any stabilizer that functions to maintain the activity ofthe tissue adhesive upon administration to the patient can be used in practicing the invention.
  • stabilizers include, but are not limited to Tris (trishydroxymethylaminomethane), PIPES (Piperazine-N,N-bis(2-ethane-sulfonic acid, 1.5 sodium salt), imidazole, and MOPS (3-(N-Mo ⁇ holine) propanesulfonic acid).
  • Suitable preservatives include sodium azide, thimerosal, BHA, BHT. Other preservatives that function to prevent the growth of microorganisms that would damage the component system is suitably added to the adhesive components.
  • Collagen a collagen analog or a collagen-containing conjugate can be added to increase the rate of gelation, and also to thicken the adhesive composition and augment cohesiveness.
  • the amount of collagen to be added can be easily determined by varying the amount of collagen and chosing that concentration of collagen which gives the desired result.
  • the collagen may be atelopeptide collagen or telopeptide collagen.
  • Animal or human-based collagen is suitably used and can be purified using methods well known to those of skill in the art and described in U.S. Patent No. 4,233,360. These collagen preparations also are available commercially from a supplier such as Collagen Co ⁇ . (Palo Alto, CA) under the tradename Zyderm II®.
  • Other biomaterials may be used to augment either the physical performance ofthe sealant or its application in a specific repair site.
  • hydroxylapatite or tri-calcium phosphate can be inco ⁇ orated for repairs in bony tissue.
  • Attachment factors such as RGD peptide sequences can be added as well.
  • Additional biomaterials include, but are not limited to bone or hard tissue materials, plastics, particulates and metals.
  • an analog is intended to include the materials as described above having similar and different chemical or physical entities of the same material as naturally occurring in nature or purified from a native source.
  • An analog can consist of hybridized or conjugated proteins, as described in published PCT International Publication No. WO 94/16085.
  • tissue sealant additionally serves as a vehicle for delivery of these components.
  • components such as antibiotics, metabolic substances, cells and growth factors can be added.
  • Growth factors such as EGF, TGF- ⁇ , TGF- ⁇ , FGF, PDGF can be added.
  • Cytokines such as interleukin or stem cell factor also can be suitably added.
  • Antibiotics can be added and are particularly useful when the adhesive is applied to exposed wound sites such as mouth sores and burns.
  • the tissue sealant compositions can also be mixed with cells, autologous, cultured or modified, allogeneic or xenogeneic. As is apparent to those skilled in the art, the amount of an added component will vary with the use ofthe adhesive and the recipient but is easily determined by the treating physician.
  • TFPI tissue factor pathway inhibitor
  • Factor VIII and IX can be obtained from plasma as described above for the other factors using known methods.
  • Factor VIII can be obtained from anti- hemophilia A therapeutic agents (Octapharma, Immuno AG, Alpha Therapeutics, Baxter- Hyland and Armour Bayer).
  • a calcium ion chelator can also be inco ⁇ orated in an amount effective to prevent formation of a fibrin clot prior to administration while still allowing the formation of clot upon administration. The amount of chelator will vary based on the source ofthe reagents and ultimate use ofthe composition. Any calcium ion chelator that functions similarly to ethylenediaminetetraacetic acid (EDTA) in binding/chelating ions or other metal ions can be used in the practice of this invention. Examples of suitable chelators include, but are not limited to citrate, salts of citrate, ethylene-bis (oxyethylenenitolo) tetraacetic acid (EGTA) and salts of EGTA.
  • EDTA ethylenedi
  • tissue sealants ofthe present invention are applied to human (or animal) tissue which provides physiological calcium from the surrounding tissue (and optionally additional necessary components), resulting in fibrin formation.
  • tissue sealants of this invention can be used in a wide variety of procedures and surgical indications, adjunctively as a replacement for sutures, hemostatic agents, packing materials and to deliver various therapeutic agents.
  • the tissue sealants can be used in any application where the formation of a fibrin clot is desired, hemostasis is required or where prior art surgical and fibrin sealants were previously used.
  • fibrin sealants have been used in tissue remodeling and wound repair. They also have been shown to act as osteogenic or osteostimulatory agents.
  • Cardiovascular applications are numerous.
  • fibrin sealants have been used as a hemostatic sealant for vascular graft attachment, cardiovascular patches, heart valve attachment and to preclot vascular grafts.
  • Fibrin sealants are also used to deliver drugs and antibiotics. Grafting of skin with fibrin sealants has been successful for burn patients, face lifts and in rhinophyma repair.
  • compositions described herein can be used to initiate the formation of fibrin or a fibrin clot in situ. Further provided are methods of treating bleeding disorders and treating wounds in a patient. These methods require administering to the patient a therapeutically effective amount ofthe single-component adhesive composition as described herein to form fibrin.
  • administering shall mean providing the recipient or patient with the tissue sealant topically for local therapy or administered by injection intravascularly (if the sealant is to be used as an embolic agent) by combining the adhesive with a suitable pharmaceutically acceptable carrier such as phosphate buffered saline.
  • suitable pharmaceutical carriers, stabilizers and preservatives are well known to those of skill in the art and are described for example in Remington's Pharm. Sci. 15th Ed. (Mack Publ. Co., Easton (1975)).
  • Local administration ofthe adhesive can be in a single dose or multiple doses as determined by the treating physician.
  • the dosage must contain an effective amount of thromboplastin and fibrinogen, as well as any other optional components, such that administration causes fibrin formation.
  • compositions of this invention can be combined with standard carriers and preservatives to form pharmaceutical compositions, which are also within the scope of this invention. Accordingly, the use ofthe compositions described herein to prepare medicaments for promoting and/or inducing the formation of fibrin in situ, is further within the scope of this invention.
  • This invention furhter provides uses ofthe above composition for the preparation of medicaments for inducing the formation of fibrin in situ in an animal such as a rat, guinea pig, rabbit or a human patient.
  • compositions and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the combination.
  • a composition consisting essentially ofthe elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.
  • compositions show the effect of adding calcium ions and/or collagen to the tissue sealant composition. It also shows that the formulations are stable at room temperature and are effective, in vivo, as well as the impact of increasing the fibrinogen concentration on gelation time.
  • the compositions were prepared as follows: bovine source citrated plasma which served as a source of fibrinogen and Factor XIII, was recycled three times (cryoprecipitate) as prepared by a modification ofthe method of (Gestring and Lerner Vase. Surg.
  • thromboplastin (RecombiPlastin (lipidated) from Ortho Diagnostics) having a nominal thromboplastin concentration of 200 ng/ml; and Zyderm II collagen (65 mg/ml)(Collagen Co ⁇ ., Palo Alto, CA).
  • TP thromboplastin
  • Zyderm II collagen 65 mg/ml
  • the suitability ofthe single-component tissue sealant as a hemostatic agent was evaluated in a standardized rodent liver incision model and the results are shown in Table VI.
  • a midline incision transecting the abdomen was made in an anesthetized rat.
  • the liver was elevated and exposed.
  • a lobe was completely bisected anterior to posterior.
  • the sealant was applied along the incision and the time for visible bleeding to stop was recorded.
  • Fibrin sealant and a fibrin-collagen composite tissue adhesive containing thrombin was also tested.
  • Prior Art Fibrin Sealant (fibrinogen, 60 mg/mL; thrombin, 15 200 U/mL; and CaCl 2 , 40 mM)
  • the single component sealant is nearly as effective as the two component
  • tissue adhesive is more effective than the prior art fibrin sealant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne des compositions de fermeture tissulaire pouvant se formuler en un seul composant. Ces compositions contiennent, comme éléments essentiels, de la thromboplastine et du fibrinogène. Il es également possible d'ajouter à la composition des facteurs de coagulation sanguine tels que les Facteurs II, V, VII, X et XIII. L'invention concerne également des procédés favorisant l'adhésion tissulaire et/ou l'hémostase tissulaire par administration des compositions d'adhésion tissulaire de l'invention.
EP97907707A 1996-02-20 1997-02-19 Compositions de fermeture tissulaire et procedes d'utilisation Withdrawn EP0885020A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1197396P 1996-02-20 1996-02-20
US11973P 1996-02-20
PCT/US1997/002614 WO1997029792A1 (fr) 1996-02-20 1997-02-19 Compositions de fermeture tissulaire et procedes d'utilisation
2000-11-09

Publications (1)

Publication Number Publication Date
EP0885020A1 true EP0885020A1 (fr) 1998-12-23

Family

ID=21752768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97907707A Withdrawn EP0885020A1 (fr) 1996-02-20 1997-02-19 Compositions de fermeture tissulaire et procedes d'utilisation

Country Status (3)

Country Link
EP (1) EP0885020A1 (fr)
JP (1) JP2002514948A (fr)
WO (1) WO1997029792A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062828A1 (fr) 1996-04-30 2000-10-26 Medtronic, Inc. Fibrine autologue d'obturation et ses methodes de fabrication
DE19781869B4 (de) * 1996-04-30 2006-10-12 Medtronic, Inc., Minneapolis Verfahren zur Herstellung eines autologen Fibrin-Klebers und autologer Fibrin-Kleber
DE29723807U1 (de) 1996-04-30 1999-11-04 Medtronic Inc Autologe Fibrin-Blutstillungsmittel
JP4493857B2 (ja) * 1998-04-20 2010-06-30 メドトロニック，インコーポレイテッド 自家移植フィブリンシーラント及び同種を作成する方法
AU764347B2 (en) * 1998-12-02 2003-08-14 Vivolution A/S Spray delivery of cells
US20030103960A1 (en) * 1999-12-22 2003-06-05 Pierre Philippart Sealant and bone generating product
EP1239894B1 (fr) * 1999-12-22 2005-03-09 Henogen S.A. Produit pour generer des os
ATE300953T1 (de) * 2000-05-10 2005-08-15 Novo Nordisk Healthcare Ag Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
WO2002055102A1 (fr) * 2001-01-10 2002-07-18 U.S. Army Medical Research & Materiel Command Compositions pour le traitement de l'hemorragie avec un facteur active viia associe au fibrinogene
BRPI0504199B8 (pt) * 2005-09-08 2021-05-25 Ana Marisa Chudzinski Tavassi composições farmacêuticas baseadas em lopap e usos das ditas composições
FR2894831B1 (fr) * 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
WO2007127841A2 (fr) 2006-04-26 2007-11-08 Arteriocyte Medical Systems, Inc. Compositions et leurs méthodes d'élaboration
CN101677836A (zh) * 2007-03-30 2010-03-24 斯鲁姆博达因公司 用于制备纤维蛋白胶的含有浓缩纤维蛋白原的组合物和相关***的制备方法
CA2716872C (fr) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Dispositif pour la promotion de l'homeostasie et/ou la cicatrisation des plaies
US8289514B2 (en) 2008-03-05 2012-10-16 Aggredyne, Inc. Systems for measuring properties of a physiological fluid suspension
KR20120125465A (ko) * 2010-01-08 2012-11-15 프로피브릭스 비.브이. 건조 분말 피브린 실란트
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
EP2745852A1 (fr) 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Compositions d'agent d'étanchéité
EP2759305A1 (fr) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Compositions hémostatiques
RU2700162C2 (ru) 2013-06-21 2019-09-13 Ферросан Медикал Дивайсиз А/С Расширенная под вакуумом сухая композиция и шприц для ее сохранения
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3470094B1 (fr) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Composition sèche comprenant un améliorateur d'extrusion
IL230151A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing a polymerization inhibitor
IL230150A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
IL231230A0 (en) * 2014-02-27 2014-08-31 Omrix Biopharmaceuticals Ltd Fibrinogen preparation
EP3613841B1 (fr) 2014-03-25 2022-04-20 Terumo BCT, Inc. Remplacement passif de supports
IL231792A0 (en) 2014-03-27 2014-08-31 Omrix Biopharmaceuticals Ltd Device and method for the preparation and administration of one-component fibrin glue
EP3198006B1 (fr) 2014-09-26 2021-03-24 Terumo BCT, Inc. Alimentation programmée
CA2960309A1 (fr) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Composition seche destinee a etre utilisee en hemostase et cicatrisation de plaie
CN107206165B (zh) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 用于保持并混合第一和第二物质的注射器
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (fr) 2017-03-31 2020-05-27 Terumo BCT, Inc. Expansion de cellules
WO2019215274A1 (fr) 2018-05-09 2019-11-14 Ferrosan Medical Devices A/S Procédé de préparation d'une composition hémostatique
CN117098996A (zh) * 2021-03-31 2023-11-21 美国血液技术公司 止血测量装置质量控制制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
JPH02167234A (ja) * 1988-07-14 1990-06-27 Furukawa Fuaamashii:Kk 生体組織接着剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9729792A1 *

Also Published As

Publication number Publication date
JP2002514948A (ja) 2002-05-21
WO1997029792A1 (fr) 1997-08-21

Similar Documents

Publication Publication Date Title
EP0885020A1 (fr) Compositions de fermeture tissulaire et procedes d'utilisation
US5510102A (en) Plasma and polymer containing surgical hemostatic adhesives
CA2111193C (fr) Composition comprenant de la fibrine ou du fibrinogene et un polymere biodegradable et biocompatible utilise pour traiter les tissus
EP0993311B1 (fr) Compositions contenant de la thrombine et du collagene microfibrillaire; procede de preparation et d'utilisation de ces compositions
US6440427B1 (en) Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US6410260B2 (en) Fibrin glue without fibrinogen and biosealant compositions and methods
AU716137B2 (en) Lyophilized collagen-based biomaterials, process of preparation and uses thereof
JP5801789B2 (ja) トロンビンを含まない生物学的接着剤及びその医薬としての使用
US20050118156A1 (en) Storage-stable fibrin sealant
AU2006204461C1 (en) Supplemented matrices for the repair of bone fractures
US20040198647A1 (en) Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20120156284A1 (en) Enhanced biological autologous tissue adhesive composition and methods of preparation and use
EP0651655A1 (fr) Reduction d'hemorragie microvasculaire en cours de chirurgie par blocage d'activation de proteine c
CA2247133A1 (fr) Compositions de fermeture tissulaire et procedes d'utilisation
Ornberg et al. Localization of topically applied TFPI binding sites in an intimectomized microvessel
CN116531551A (zh) 一种基于纤维蛋白原的贴片及其制备方法和应用
Chevrel et al. Use of Fibrin Glues in the Surgical Treatment of Incisional Hernias
Chevrel et al. Treatment of Incisional Hernias

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000901